Stock ORY ORYZON GENOMICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

All News Oryzon Genomics S.A.

Equities

ORY

ES0167733015

Market Closed - BME
Other stock markets
 09:05:18 25/06/2024 pm IST 		Pre-market 11:02:01 am
1.88 EUR -0.53% Intraday chart for Oryzon Genomics S.A. 1.89 +0.53%
14/06 Oryzon Genomics S.A. Presents Preliminary Data from Ongoing Phase Ib Frida Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory Flt3-Mut Aml Patients At Eha-2024 CI
06/05 Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory FLT3-mut AML Patients at EHA-2024
AQ
Oryzon Genomics S.A. Presents Preliminary Data from Ongoing Phase Ib Frida Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory Flt3-Mut Aml Patients At Eha-2024
CI
Oryzon Genomics S A : presents preliminary data from ongoing Phase Ib FRIDA trial with iadademstat plus gilteritinib in relapsed/refractory FLT3 mut AML patients at EHA 2024
PU
Oryzon Genomics S A : announces journal publication of final Phase IIa ALICE results with iadademstat in The Lancet Hematology
PU
Oryzon Genomics S A : to provide corporate progress updates at several events in June
PU
ORYZON Selected as Associated Partner in the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)
AQ
Oryzon Genomics S A : to provide corporate progress updates at several events in May
PU
Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Oryzon Genomics S A : reports financial results and corporate update for quarter ended March 31, 2024
PU
Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat
CI
Oryzon Genomics S A : secures another important patent for its lead CNS asset, vafidemstat
PU
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
AQ
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
CI
Oryzon Genomics S A : to provide corporate progress updates at several events in April
PU
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023
AQ
Oryzon Genomics S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
ORYZON to Provide Corporate Progress Updates at Several Events in February-March
AQ
ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024
AQ
ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)
AQ
Oryzon Genomics, S.A. Announces Topline Results from Phase IIb Portico Study of Vafidemstat in Borderline Personality Disorder
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ORY Stock
  4. News Oryzon Genomics S.A.